guamerin

a cysteine-rich polypeptide of 57 amino acid residues; from a Korean native leech Hirudo nipponia; a human leukocyte and porcine pancreatic elastase-specific inhibitor; has 51% sequence homology with hirustasin; amino acid sequence given in first source

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Choi, Ho Soon: 1 article (07/2008)
2.	Hahm, Joon Soo: 1 article (07/2008)
3.	Jo, Yun Ju: 1 article (07/2008)
4.	Jun, Dae Won: 1 article (07/2008)
5.	Jung, Kyung Hwan: 1 article (07/2008)
6.	Kang, Joo Seop: 1 article (07/2008)
7.	Lee, Oh Young: 1 article (07/2008)
8.	Park, Il Gyu: 1 article (07/2008)
9.	Choi, Seung Jin: 1 article (06/2004)
10.	Chung, Soo Il: 1 article (06/2004)

Related Diseases

1.	Pancreatitis 07/01/2008 - "Fifty Sprague-Dawley rats were divided into three groups: a saline-infused control group (I), a cerulein-induced acute pancreatitis group (II), and a cerulein plus guamerin infusion group (III). " 07/01/2008 - "We aimed to investigate the effects and the possible mechanism of a new human leukocyte elastase inhibitor (recombinant guamerin) in the treatment of cerulein-induced acute pancreatitis in rats. " 07/01/2008 - "The effects of a new human leukocyte elastase inhibitor (recombinant guamerin) on cerulein-induced pancreatitis in rats." 04/01/1999 - "In this study we show that a novel elastase inhibitor, guamerin-derived synthetic peptide (GDSP), improves the parameters of cerulein-induced acute pancreatitis in the rat. " 07/01/2008 - "Guamerin (1-2 micromol/kg/h) was infused continuously in group III. The severity of pancreatitis was determined biochemically, histologically, and by cytokine changes between groups I, II and III. Significant differences in serum amylase, lipase, and pancreatic wet weight were observed in each group, respectively (group I; 2346.2 IU/L, 9.9 IU/L, 1.4+/-0.3 g, group II; 13,596.8 IU/L, 7439.4 IU/L, 2.2+/-0.5 g, group III; 9443.2 IU/L, 4516.3 IU/L, 1.7+/-0.6 g). "
2.	Wounds and Injuries (Trauma) 06/30/2004 - "Paradoxical effects of elastase inhibitor guamerin on the tissue repair of two different wound models: sealed cutaneous and exposed tongue wounds." 06/30/2004 - "The aim of this study was to evaluate affects of leukocyte elastase suppression and PMN infiltration on wound healing in mouse by administering the recombinant elastase inhibitor guamerin (rEIG) in two different wound models; 1) impaired pin-punctured dorsal mucosa of anterior tongue wound, 60 mice, treated with saline containing rEIG that were fed ad libitum and 2) stable linear excisional cutaneous wound, 40 mice, covered with fibrin sealant containing rEIG. "
3.	Inflammation (Inflammations) 07/01/2008 - "Histologic gradings and severity, such as vacuolization, inflammation, lobular disarray, and edema of the pancreas, were significantly lower in the cerulein plus guamerin infusion group III. Recombinant guamerin, a new human leukocyte elastase inhibitor, may decrease the severity of pancreatitis and diminish pancreatic acinar cell injury by inhibition of neutrophilic infiltration and cytokine activation in the initial stage of cerulein-induced acute pancreatitis in rats."
4.	Edema (Dropsy) 07/01/2008 - "Histologic gradings and severity, such as vacuolization, inflammation, lobular disarray, and edema of the pancreas, were significantly lower in the cerulein plus guamerin infusion group III. Recombinant guamerin, a new human leukocyte elastase inhibitor, may decrease the severity of pancreatitis and diminish pancreatic acinar cell injury by inhibition of neutrophilic infiltration and cytokine activation in the initial stage of cerulein-induced acute pancreatitis in rats."

Related Drugs and Biologics

1.	Pancreatic Elastase (Elastase)
2.	Ceruletide
3.	Leukocyte Elastase (Neutrophil Elastase)
4.	Fibrin Tissue Adhesive (Fibrin Sealant)
5.	Peptides (Polypeptides)
6.	Cytokines
7.	Lipase (Acid Lipase)
8.	Amylases
9.	peptide A
10.	human SERPINB1 protein